Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.

中文翻译：

---

间充质干细胞治疗 COVID 19 的临床试验

间充质干细胞（MSC）由于其免疫调节、抗炎、组织修复和再生特性，正在被研究作为一种新型病毒性疾病的治疗方法，但其确切过程尚不清楚。研究发现，MSC 疗法可通过改善肺部微环境，有效降低 SARS-CoV-2 感染后免疫系统的过度激活并增加内源性愈合。许多关于间充质干细胞的研究已经同时进行，我们可以通过收集和统计分析这些研究的数据来帮助加快这些研究的有效性。基于临床试验中发现的临床试验信息。 gov 和 2020 年 11 月 16 日，其中包括使用 MSC 治疗 COVID-19 患者领域的 63 项临床试验，根据该领域研究不断增加的趋势，并在荟萃分析研究的帮助下，有可能希望间充质干细胞的承诺有一天能够实现。本研究调查了 MSC 对 COVID-19 的潜在治疗应用。